This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Topiramate and ocular syndrome

Authoring team

  • an ocular syndrome has been reported associated with the use of topiramate - the syndrome is characterised by acute myopia and secondary angle-closure glaucoma

  • as of August 17, 2001, there had been 23 reported cases of this ocular syndrome; 22 in adults and 1 in a paediatric patient. This information was base on the post marketing experience in more than 825,000 patients (1)

  • symptoms of ocular syndrome generally occur within 1 month of the start of treatment and include decreased visual acuity and/or ocular pain. Ophthalmological findings include hyperaemia, bilateral myopia, anterior chamber shallowing, and increased intra-ocular pressure with or without mydriasis. Also there may also be supraciliary effusion resulting in anterior displacement of lens and iris. Treatment includes discontinuation of topiramate treatment as rapidly as is clinically feasible and appropriate measures to reduce intraocular pressure

  • please consult summary of product characteristics for more details

Reference:

  • (1) Janssen-Cilag Ltd (15/10/2001). Letter - Important Safety Information - Topamax (R) Tablets and Topamax (R) Sprinkle Capsules (Topiramate).

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.